DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.

Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Satellogic Inc ( $SATL ) Vertically Integrated Earth Observation & Persistent Monitoring March14 DD

Satellogic is one of those names that can look much bigger, much smaller, much safer or much more dangerous depending on the exact week in which an investor or trader meets the story. In a hot tape, the company can be pitched as a pure-play Earth observation platform exposed to sovereign demand, AI-driven geospatial workflows and a possible shift toward more recurring monitoring contracts. In a colder tape, exactly the same company can be described as a low-margin, cash-consuming, serially dilutive small cap whose commercial wins still need to prove that they can scale into a durable business rather than a string of eye-catching press releases. Both sides are seeing a piece of the truth. That is why a SATL report is only useful if it keeps those two realities on the page at the same time.
Intuitive Machines Inc ( $LUNR ) Deep Dive March 14/2026

Intuitive Machines Inc (LUNR) is a diversified space infrastructure company with four core business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products & Infrastructure. Founded in 2013, IM has emerged as a prime contractor for NASA lunar missions, U.S. Department of Defense space architecture programs, and emerging commercial lunar economy players. The company's 2024 milestone—landing the Nova-C lunar lander on the Moon's South Pole region—marked the first crewed-space-capable U.S. lunar return since Apollo 17, positioning IM as the dominant platform for American lunar access for the foreseeable future.
Aldeyra Therapeutics ( $ALDX ): past, present and future around reproxalap and the March 2026 FDA decision

A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision.
ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real

Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.”
5 energy stocks under $2 billion to watch in march ( $PUMP $EGY $RNGR $GEOS $KLXE )

This article compares five U.S.-listed energy names below $2 billion in market value that could benefit, directly or indirectly, from a stronger oil tape, firmer field activity, or renewed investor appetite for smaller-cap energy exposure: ProPetro (PUMP), VAALCO Energy (EGY), Ranger Energy Services (RNGR), Geospace Technologies (GEOS) and KLX Energy Services (KLXE).
Immutep Limited ( Nasdaq $IMMP ) after TACTI-004 futility

Core fact
On March 13, 2026 Immutep said the Independent Data Monitoring Committee recommended discontinuing the registrational Phase III TACTI-004 study following the planned futility analysis.
US Airlines in the Energy Storm ( $AAL ) ( $DAL ) ( $UAL )

The current energy crisis is not hitting every U.S. airline the same way. Higher oil matters, but higher jet fuel matters more, and the market is now separating airlines by pricing power, customer mix, balance-sheet flexibility and margin resilience rather than by simple traffic growth.
XTI Aerospace ( $XTIA ): Defense Drones and Urban Air Mobility at an Inflection Point

XTI Aerospace, Inc. (NASDAQ: XTIA) is an aerospace and technology platform combining vertical flight aircraft development, unmanned aircraft systems, and enterprise drone distribution. As of March 2026, the company is in the early scaling phase following its transformational November 2025 acquisition of Drone Nerds.
Firefly Aerospace Inc ( $FLY ) March 12 2026

Thursday’s move in Firefly Aerospace was not just a momentum spike on a cool rocket headline. The market reacted because Alpha Flight 7 checked several boxes at once. Firefly did not merely launch. It reached orbit, delivered a Lockheed Martin technology demonstrator, completed a stage-two engine relight, and used the mission to validate meaningful pieces of its next hardware iteration, Alpha Block II. In the space business, especially for a newer public company still earning its institutional reputation, those are not cosmetic details.
BlackSky (NYSE: $BKSY) — why the story looks stronger in March 2026

BlackSky has turned a familiar speculative space name into something the market is finally trying to reprice as real defense-tech infrastructure. Fourth-quarter numbers were solid, backlog expanded, a new seven-figure NGA Luno delivery order added another official validation point, and then management followed with two operational milestones that matter more than the typical space-company headline: Gen-3 first light arrived within hours, and the fourth Gen-3 satellite was commissioned in less than a week, opening general availability of the company’s best-in-class 35-centimeter imagery and AI-enabled analytics to global customers. The bullish case is no longer based only on a distant dream of “space growth.” It is increasingly built on the idea that BlackSky is becoming a usable, taskable, software-connected intelligence layer for governments that need decisions faster, not just prettier satellite pictures.
Ondas and Palantir ( $ONDS ) ( $PLTR ) a real defense-tech stack? (Part 2)

The first article explained the announcement. This second one tackles the harder question: whether the Ondas–Palantir–World View structure can evolve into something commercially meaningful, or whether the market is still looking at a strategically attractive partnership that remains too early to change fundamentals.
Palantir Ondas and World View just sketched a much bigger story than a normal partnership headline (Part 1)

Palantir, Ondas and World View announced a partnership to develop a next-generation multi-domain intelligence platform, using Palantir AIP across production, mission planning and edge operations.
Artiva Biotherapeutics Inc ( $ARTV ) March 11th

Artiva Biotherapeutics rallied sharply after its full-year 2025 results and business update put the spotlight back where biotech traders care most: near-term clinical readouts, FDA path visibility, analyst support, and whether the balance sheet is strong enough to carry the story into the next real value-inflection point.
Hims & Hers ( $HIMS ) from GLP-1 backlash to a big strategic reset

A few weeks ago the core question was whether Hims had pushed the GLP-1 trade too far and invited a regulatory and legal backlash that could damage one of the market’s favorite growth stories. That question has not disappeared. But the story has changed meaningfully. The company now has a formal strategic shift in U.S. weight loss, a public collaboration with Novo Nordisk, access to branded Wegovy and Ozempic on the platform, a dropped lawsuit, and still the pending Eucalyptus acquisition that could reshape the company from a fast U.S. telehealth operator into a broader global consumer-health platform.
Ocugen Inc ( $OCGN ) why the stock exploded, what the dual analyst boost really means

Ocugen came back to life on a violent session after a stacked sell-side day: one firm initiated with an Outperform and a $10 target, while another raised its target to $22 from $15 and kept a Buy rating. But the move does not sit on analyst language alone. It lands on top of a Phase 3 enrollment-complete lead program, a visible BLA path, multiple ocular follow-on catalysts, a high-beta retail base, meaningful short interest, and a balance sheet that is improved from panic but still nowhere near bulletproof.
Planet Labs ( $PL )moving toward strategic infrastructure

The new delay on Middle East imagery is not enough, by itself, to make a full article. But as an editorial trigger, it is strong. It forces a bigger question: is Planet still mainly a commercial satellite-imagery company, or is it becoming a strategic information utility that increasingly operates inside the security architecture of the United States and its allies?
Rocket Pharmaceuticals Inc ( $RCKT ) refreshes its ATM 17 days before the March 28 PDUFA

This was not a classic overnight equity raise. Rocket filed a new ATM framework with Cantor Fitzgerald, terminated the prior TD/Cowen agreement, and did so with the March 28, 2026 PDUFA for KRESLADI now close enough to matter in every financing read-through.
X and the Nasdaq question

A careful bilingual deep dive on whether X could realistically find a route to Nasdaq exposure after today’s Reuters reports, why the answer is more indirect than many headlines suggest, and how payments, regulation, competition and corporate structure change the picture.
Capricor Therapeutics Inc ( $CAPR ) FDA PDUFA Approval Target (August 22, 2026)

On March 10, 2026, Capricor Therapeutics announced that the FDA has lifted its Complete Response Letter (CRL) and resumed review of the Biologics License Application (BLA) for Deramiocel. The agency assigned a new PDUFA target action date of August 22, 2026—a pivotal moment after months of regulatory uncertainty.
Castellum ($CTM) — 2025 repaired the story

Castellum came out of 2025 looking cleaner, less leveraged and more credible than it did a year earlier. Revenue grew, operating losses narrowed sharply, cash improved, debt was almost fully gone by year-end and then fully eliminated shortly after. The central question now is no longer whether CTM can tell a better story, but whether it can turn backlog, contract wins and pipeline into durable margins and more repeatable cash generation in 2026.